• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comments on: High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localize prostate cancer: toxicity and 6-years biochemical results.

作者信息

Lee W Robert

机构信息

Professor of Radiation Oncology, Duke University School of Medicine, Durham, NC.

出版信息

Brachytherapy. 2019 May-Jun;18(3):426. doi: 10.1016/j.brachy.2019.01.009. Epub 2019 Feb 21.

DOI:10.1016/j.brachy.2019.01.009
PMID:30797697
Abstract
摘要

相似文献

1
Comments on: High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localize prostate cancer: toxicity and 6-years biochemical results.对以下文献的评论：高剂量率组织间近距离放射治疗作为单疗法，单次给予20.5 Gy治疗局限性前列腺癌：毒性反应及6年生化结果
Brachytherapy. 2019 May-Jun;18(3):426. doi: 10.1016/j.brachy.2019.01.009. Epub 2019 Feb 21.
2
High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results.高剂量率组织间近距离放射疗法单次20.5 Gy作为局限性前列腺癌的单一疗法：毒性及6年生化结果
Brachytherapy. 2018 Nov-Dec;17(6):845-851. doi: 10.1016/j.brachy.2018.06.002. Epub 2018 Jul 18.
3
High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results.高剂量率间质近距离治疗作为局限性前列腺癌的单一疗法：治疗演变和成熟结果。
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):672-8. doi: 10.1016/j.ijrobp.2012.07.004. Epub 2012 Aug 25.
4
High-dose-rate brachytherapy as a monotherapy for prostate cancer--Single-institution results of the extreme fractionation regimen.高剂量率近距离放射疗法作为前列腺癌的单一疗法——极端分割方案的单机构研究结果
Brachytherapy. 2015 May-Jun;14(3):359-65. doi: 10.1016/j.brachy.2015.01.004. Epub 2015 Feb 28.
5
Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.影像引导适形高剂量率近距离放疗用于预后不良前列腺癌患者的中期报告：威廉·博蒙特医院II期剂量递增试验
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52. doi: 10.1016/s0360-3016(00)00436-3.
6
Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.前瞻性剂量递增 II 期试验的长期结果：间质脉冲剂量率近距离放疗作为中高危前列腺癌的增敏剂。
Radiother Oncol. 2012 Aug;104(2):181-6. doi: 10.1016/j.radonc.2012.07.003. Epub 2012 Jul 30.
7
High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.高剂量率近距离放射治疗单药治疗中危前列腺癌，不进行雄激素剥夺治疗。
Brachytherapy. 2017 Mar-Apr;16(2):299-305. doi: 10.1016/j.brachy.2016.11.002. Epub 2016 Dec 10.
8
High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.与低剂量率钯籽源相比，高剂量率近距离放射疗法作为前列腺癌单一疗法可降低毒性。
J Urol. 2004 Mar;171(3):1098-104. doi: 10.1097/01.ju.0000113299.34404.22.
9
Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.19Gy单次分割高剂量率近距离放射治疗低危和中危前列腺癌男性患者的初步良好结果
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):98-106. doi: 10.1016/j.ijrobp.2016.08.011. Epub 2016 Nov 9.
10
Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.低剂量率¹²⁵I 前列腺近距离放疗作为低、中、高危前列腺癌单一疗法的长期疗效和毒性。
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):884-93. doi: 10.1016/j.ijrobp.2015.02.047. Epub 2015 May 8.

引用本文的文献

1
Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study.MRI 靶向单次分割 HDR 近距离治疗局限性前列腺癌的可行性：ProFocAL 研究。
J Cancer Res Clin Oncol. 2023 Jul;149(8):5397-5404. doi: 10.1007/s00432-022-04491-3. Epub 2022 Nov 29.